Compare Stocks → New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison CVE:EMHCVE:IGXNASDAQ:PMNNASDAQ:VLON Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMHEmerald Health TherapeuticsC$0.26-3.8%C$0.26C$0.15▼C$0.53C$52.28MN/A644,760 shs384,329 shsIGXIntelGenx TechnologiesC$0.58+1.8%C$0.58C$0.17▼C$0.85C$87.32MN/A56,279 shs11,848 shsPMNProMIS Neurosciences$1.97+5.9%$2.04$0.95▼$8.95$35.27M0.6740,588 shs13,493 shsVLONVallon Pharmaceuticals$0.52+2.0%$0.67$0.21▼$12.92$6.98M-1.145.78 million shs44,128 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMHEmerald Health Therapeutics0.00%0.00%0.00%0.00%0.00%IGXIntelGenx Technologies0.00%0.00%0.00%0.00%0.00%PMNProMIS Neurosciences+5.91%-16.17%+0.51%-10.86%-62.12%VLONVallon Pharmaceuticals-2.54%-3.04%-32.50%+87.50%-96.85%Now Open: Crypto emergency update (Ad)During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEMHEmerald Health TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AIGXIntelGenx TechnologiesN/AN/AN/AN/AN/AN/AN/AN/APMNProMIS Neurosciences2.7897 of 5 stars3.54.00.00.03.11.70.6VLONVallon PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMHEmerald Health TherapeuticsN/AN/AN/AN/AIGXIntelGenx TechnologiesN/AN/AN/AN/APMNProMIS Neurosciences3.00Buy$8.00306.09% UpsideVLONVallon PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMHEmerald Health TherapeuticsC$13.02M4.02C$0.33 per share0.78C$0.40 per share0.64IGXIntelGenx TechnologiesC$1.75M49.95C$0.08 per share7.16C$0.05 per share12.89PMNProMIS Neurosciences$10K3,735.32N/AN/A$0.20 per share9.85VLONVallon Pharmaceuticals$100K69.76N/AN/A$0.18 per share2.87Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMHEmerald Health TherapeuticsN/A-C$0.70N/A∞N/AN/AN/AN/AN/AIGXIntelGenx TechnologiesN/A-C$0.08N/A∞N/AN/AN/AN/AN/APMNProMIS Neurosciences-$13.21M-$1.13N/AN/AN/AN/AN/A-141.23%5/20/2024 (Estimated)VLONVallon Pharmaceuticals-$7.02M-$0.78N/A∞N/AN/A-230.48%-124.89%N/ALatest PMN, VLON, EMH, RUA, and IGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023PMNProMIS NeurosciencesN/A-$0.09-$0.09-$0.09N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMHEmerald Health TherapeuticsN/AN/AN/AN/AN/AIGXIntelGenx TechnologiesN/AN/AN/AN/AN/APMNProMIS NeurosciencesN/AN/AN/AN/AN/AVLONVallon PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMHEmerald Health Therapeutics35.452.972.61IGXIntelGenx Technologies164.622.772.69PMNProMIS NeurosciencesN/A1.461.46VLONVallon PharmaceuticalsN/A2.292.29OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMHEmerald Health TherapeuticsN/AIGXIntelGenx TechnologiesN/APMNProMIS Neurosciences50.13%VLONVallon Pharmaceuticals8.74%Insider OwnershipCompanyInsider OwnershipEMHEmerald Health TherapeuticsN/AIGXIntelGenx TechnologiesN/APMNProMIS Neurosciences10.30%VLONVallon Pharmaceuticals37.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableEMHEmerald Health Therapeutics161205.03 millionN/ANot OptionableIGXIntelGenx Technologies48150.55 millionN/ANot OptionablePMNProMIS Neurosciences618.96 million17.01 millionNot OptionableVLONVallon Pharmaceuticals313.48 million8.45 millionNot OptionablePMN, VLON, EMH, RUA, and IGX HeadlinesSourceHeadlineQuestcor Pharmaceuticals,forbes.com - July 21 at 11:15 PMVallon Pharmaceuticals' shareholders approve reverse merger with California companybizjournals.com - April 20 at 11:09 PMVallon Pharmaceuticals Announces Stockholder Approval of Merger with GRI Bio, Inc. and Reverse Stock Splitfinance.yahoo.com - April 20 at 11:09 PMVallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023finance.yahoo.com - April 12 at 5:20 PMLab Notes: CHOP gets $10M research gift; Vallon seeks greater shareholder support for mergerbizjournals.com - April 7 at 3:29 PMVallon Pharmaceuticals Provides an Update on Proxy Voting for the Proposed Merger with GRI Bio and Urges Stockholders of Record as of March 6, 2023 to Vote by April 11, 2023, at 11:59 PM ETfinance.yahoo.com - April 4 at 1:30 PMVallon Pharmaceuticals Inc.: Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Resultsfinanznachrichten.de - February 24 at 6:18 PMVallon Pharmaceuticals Reports Fiscal Year 2022 Financial Resultsfinance.yahoo.com - February 24 at 8:19 AMIs Vallon Pharmaceuticals Inc (VLON) recent surge justifiedbenzinga.com - February 14 at 6:48 PMVallon Pharmaceuticals and GRI Bio to Present at the Virtual Investor 2023 Companies to Watch Eventfinance.yahoo.com - January 11 at 9:46 AMSHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Vallon Pharmaceuticals, Inc. - VLONbenzinga.com - December 27 at 6:38 PMVallon rockets as it announces merger with GRI Biothepharmaletter.com - December 15 at 11:44 AMSay goodbye to Vallon as a low-profile NKT cell startup steps into its battered shoes on Nasdaqendpts.com - December 14 at 12:21 PMVallon Pharmaceuticals to merge with California biotech firm in 'best path forward'bizjournals.com - December 14 at 12:21 PMWhat's Going On With Vallon Pharmaceuticals Stock Today?msn.com - December 14 at 12:21 PMWhy Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarketbenzinga.com - December 14 at 7:15 AMVallon Pharmaceuticals and GRI Bio Enter into Merger Agreement with Goal of Advancing Innovative Pipeline of NKT Cell Regulatorsfinance.yahoo.com - December 13 at 4:19 PMVallon Pharmaceuticals Reports Third Quarter 2022 Financial Resultsfinance.yahoo.com - November 3 at 8:06 PMVallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - July 28 at 12:15 PMVallon Pharmaceuticals, Inc. (VLON)finance.yahoo.com - July 20 at 12:07 AMVallon Pharmaceuticals plans $3.9M stock sale to support exploration of strategic alternativesbizjournals.com - May 16 at 8:29 PMVallon Pharmaceuticals to raise $3.9M in stock offeringseekingalpha.com - May 13 at 4:14 PMVallon Pharmaceuticals Announces $3.9 Million Registered Direct Offeringfinance.yahoo.com - May 13 at 4:14 PMVallon Pharma Posts Additional Data From SEAL Study Of Formulated CNS Stimulantfinance.yahoo.com - May 12 at 3:50 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsEmerald Health TherapeuticsCVE:EMHEmerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis for medical purpose in Canada. The company is also involved in developing natural health products. It offers dried cannabis strains, pre-rolls, and cannabis oil products to its medical patients. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.IntelGenx TechnologiesCVE:IGXIntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid addition; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, and INT0053/2020. The company has licensing, development, and supply agreement with Tilray, Inc. and Gensco Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.ProMIS NeurosciencesNASDAQ:PMNProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Vallon PharmaceuticalsNASDAQ:VLONVallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.